R&D channel feed – Endpoints News

R&D channel feed

Aligos chops off a hepatitis B program — again — after a patient was briefly hospitalized

4 years ago

Eli Lilly chief Dave Ricks rides a winning season to a rich, $21.5M pay package as successes outweigh setbacks

4 years ago

Tonix's lead drug fails PhIII again, sending stock even closer to zero

4 years ago

Tiny Vallon’s attempt at breaking into the big Adderall market just went up in smoke — and so did its stock

4 years ago

ImmunoGen’s ovarian cancer comeback not as rosy as expected as progression-free survival lags

4 years ago

Marinus completes its turnaround with first approval of sole drug, winning a PRV for its efforts

4 years ago

On heels of landmark approval, Bristol Myers Squibb embarks on billion-dollar oncology deal with metastatic cancer startup

4 years ago

FDA OKs Bristol Myers Squibb’s LAG-3 drug, approving first new class of checkpoint inhibitor in 8 years

4 years ago

Hot on Roche’s heels, Merck spells out mixed Keytruda data in adjuvant NSCLC

4 years ago

Apellis rises on long-term data for Soliris challenger after mixed PhIII readout, and analysts are more bullish on approval

4 years ago

A little biotech crows about its Covid-19 'one and done' PhIII, causing at least one top analyst to change his tune as shares soar

4 years ago

Final ACTIV-2 enrollment is stopped, leaving tiny biotech without a second PhIII study

4 years ago

Biogen closes out its ophthalmology R&D work, dumping off a C3 therapy

4 years ago

Trying to nip at AstraZeneca's heels, Lilly and Boehringer Ingelheim stop a PhIII Jardiance study early in kidney disease

4 years ago

Sanofi partners up with dominant ADC player Seagen, doubling down on oncology in hunt for a better pipeline

4 years ago

With new RSV antibody, Sanofi looks to avoid a repeat of a 20-year-old pricing controversy

4 years ago

An Altos Labs rival? Genentech throws its hat into buzzy 'cellular rejuvenation' field

4 years ago

Merck suffers rare Keytruda setback as the blockbuster fails a PhIII prostate cancer test with Lynparza

4 years ago

Novo Nordisk, Gates Foundation pledge $90M to fund antiviral research for the next pandemic

4 years ago

Roiled by senior-level exits, Jim Wilson’s Passage Bio retrenches, chopping back on staff as it extends cash runway

4 years ago

Rooting for a come-from-behind win, Blackstone infuses $330M into Sanofi's CD38 development plan

4 years ago

AnaptysBio drops another indication for lead drug after it fails a second PhII study in 12 months

4 years ago

After rolling up nothing but positive PhIII data for the FDA and EMA, Astellas' drug for hot flashes registers a fail in Asia

4 years ago

Exelixis throws in the towel on early-stage liver cancer after final readout shows OS flop

4 years ago

First page Previous page 143 144 145146147 148 149 Next page Last page